1951 (1951) Fair Value & Analysis

Healthcare · Market cap HK$5.1B

1 1951 1951 · HK

PriceHK$2.02

Fair ValueHK$0.7200

Upside-64.4%

Quality41/100

Watch 1951 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.3500 – HK$1.10

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Share price −11.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.93 – HK$3.37 · fair‑value band HK$0.3500 – HK$1.10 · the HK$2.02 price screens above the HK$0.7200 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1951 (1951) currently trades at HK$2.02, while our model-based Fair Value estimate is HK$0.7200 — implying the stock looks roughly 64.4% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1951 generated revenue of HK$2.6B at a net margin of -36.9%. Revenue declined 0.5% year over year. It earns a return on equity of -10.1%. Net debt stands at HK$2.1B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.6B

Revenue growth (YoY) -0.5%

Net margin -36.9%

Return on equity -10.1%

Free cash flow HK$218M FY2025

Operating margin 8.4%

More key figures

EPS (TTM) HK$-0.3900

Dividend yield 1.9%

EPS growth (YoY) -32.5%

Net debt HK$2.1B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1951 reported revenue of HK$2.6B in FY2025 versus HK$1.8B in FY2021, a compound +8.8%/yr. Reported net income was −HK$951M in FY2025.

Revenue +8.8%/yr

FY21 HK$1.8B

FY22 HK$2.4B

FY23 HK$2.8B

FY24 HK$2.8B

FY25 HK$2.6B

Net income

FY21 HK$340M

FY22 HK$121M

FY23 HK$345M

FY24 HK$283M

FY25 −HK$951M

Is 1951 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$97.60	R$115.75	+19%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1951 (1951) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.7200 versus a price of HK$2.02 — about −64% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1951?

Our model-based fair value for 1951 is HK$0.7200 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.02.

What is the quality score of 1951?

1951 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1951 (1951)?

1951 reported trailing-twelve-month revenue of about HK$2.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1951?

The net profit margin of 1951 is about -36.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

Does 1951 pay a dividend?

1951 currently shows a dividend yield of about 1.88% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.